Sunday, November 7, 2021
- 8:30AM-10:30AM
-
Abstract Number: 0766
Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)- 8:30AM-10:30AM
-
Abstract Number: 0934
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-Radiographic Axial Spondylarthritis Patients Through 52 Weeks: Data from 3 Phase III, Randomized, Controlled Trials
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)- 8:30AM-10:30AM
-
Abstract Number: 0821
Baseline Characteristics Predictive of Remission in Patients with RA Following Treatment with IV Abatacept: Post Hoc Analysis of a Real-world Observational Study
RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)- 8:30AM-10:30AM
-
Abstract Number: 0807
Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA)
RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)- 8:30AM-10:30AM
-
Abstract Number: 0540
Behavioral Deficits May Precede Influx of Brain-Infiltrating Macrophages in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
SLE – Animal Models Poster (0534–0540)- 8:30AM-10:30AM
-
Abstract Number: 0922
Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)- 8:30AM-10:30AM
-
Abstract Number: 0818
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)- 8:30AM-10:30AM
-
Abstract Number: 0915
Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Pharmacodynamic Effects of TNF-α Inhibitory Therapy in Patients with Axial Spondyloarthritis
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)- 8:30AM-10:30AM
-
Abstract Number: 0817
Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13
RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)- 8:30AM-10:30AM
-
Abstract Number: 0573
Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)- 8:30AM-10:30AM
-
Abstract Number: 0870
Blood Brain Barrier Integrity and Brain Imaging Patterns in Patients with SLE
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)- 8:30AM-10:30AM
-
Abstract Number: 0852
Bone Marrow Lesion Segmentation Using Synthetic Data and Deep Learning Models
Research Methodology Poster (0846–0854)- 8:30AM-10:30AM
-
Abstract Number: 0754
Bridging the Gap Between Patient-Reported Outcomes and Disease-Related Outcomes in Lupus – a Feasibility Study
Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)- 8:30AM-10:30AM
-
Abstract Number: 0625
Brief Tailored Clinic Intervention (A-MATIC) Targets Nonadherence During SLE Visits: Two-year Sustainability and Outcomes